USPTO Patent Application: HRD Cancer Classification and Treatment

ChangeBridge: Patent Apps - Pharma (A61K)

Published August 29th, 2023

Detected March 23rd, 2026

Summary

The USPTO has published a patent application from Foundation Medicine, Inc. detailing systems and methods for classifying and treating homologous repair deficiency (HRD) cancers. The application describes models for identifying HRD-positive tumors and suggests combination therapies, such as FOLFIRINOX, for treatment.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260080973A1) filed by Foundation Medicine, Inc. It describes methods, devices, and systems for classifying tumors as HRD positive or negative, particularly for cancers like pancreatic cancer. The application also outlines treatment methods for HRD-positive cancers, suggesting sensitivity to combination therapies including fluorouracil and platinum-based agents like oxaliplatin (e.g., FOLFIRINOX).

As this is a patent application, it does not impose immediate regulatory obligations. However, it signals potential future developments in diagnostic tools and therapeutic approaches for HRD cancers. Companies involved in oncology drug development, diagnostics, and treatment may find the described methodologies and therapeutic combinations of interest for research and development purposes.

Source document (simplified)

← USPTO Patent Applications

SYSTEMS AND METHODS FOR CLASSIFYING AND TREATING HOMOLOGOUS REPAIR DEFICIENCY CANCERS

Application US20260080973A1 Kind: A1 Mar 19, 2026

Assignee

Foundation Medicine, Inc.

Inventors

Ethan SOKOL, Kuei-Ting CHEN, Russell MADISON

Abstract

Described herein are methods, devices, and systems for identifying a subset of a plurality of features, using one or more feature importance metrics, for training and using a homologous repair deficiency (HRD) classification model. Further described are methods, devices, and systems for classifying a tumor of a cancer, such as pancreatic cancer, as likely HRD positive or likely HRD negative, and for calling the tumor as HRD positive or HRD negative. Also described herein are methods of treating a tumor of a cancer, such as pancreatic cancer, based on the classifications. The cancer identified as HRD-positive may be particularly sensitive to a combination therapy comprising fluorouracil and a platinum-based chemotherapeutic agent (e.g., oxaliplatin), for example FOLFIRINOX.